Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SYL1801 in Healthy Volunteers
NCT04782271Phase 1Completed
- Sponsor
- Sylentis
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised trial of SYL1801 in choroidal neovascularization (CNV) (8 arms), sponsored by Sylentis. Primary endpoints: Ocular tolerability at the site of administration (cornea and conjunctiva), Maximum Plasma Concentration at 24 hours and 1 more. Started Mar 2021; status: completed.
02
Drugs
SYL1801
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT04782271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782271.